Nektar Therapeutics, traded on the NASDAQ under the symbol NKTR, is a biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. The company is known for its research in immunology and oncology. Recently, Jefferies analyst Roger Song set a price target of $99 for NKTR, suggesting a potential increase of 68.54% from its current price of $58.74.
The recent surge in NKTR's stock price, climbing over 15%, is attributed to positive developments in its clinical research. The company announced promising results from a phase 2b study of its investigational drug, rezpegaldesleukin, aimed at treating moderate to severe atopic dermatitis. This news has propelled NKTR's stock to outperform the S&P 500 index, which only saw a 0.5% increase.
The study, presented at the 2025 European Academy of Dermatology and Venereology Congress, demonstrated that rezpegaldesleukin met its primary and key secondary endpoints at week 16. The high dose of the drug achieved statistical significance in improving the eczema area and severity index compared to a placebo. Participants who continued the treatment experienced even more substantial benefits.
Interim data for patients who initially received a placebo and then switched to a 24-week high dose treatment showed significant improvement. The EASI-75 response deepened to 62%, and the vIGA-AD 0/1 response increased to 38%. These findings were presented by Dr. Jonathan Silverberg, highlighting the drug's potential in treating atopic dermatitis.
Currently, NKTR's stock is priced at $58.76, with a market capitalization of approximately $1.12 billion. The stock has fluctuated between a low of $52.13 and a high of $58.81 today, marking its highest price over the past year. The lowest price for the stock in the past year was $6.45, indicating significant growth potential.
